Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225001, P. R. China.
Analyst. 2021 Sep 7;146(17):5326-5336. doi: 10.1039/d1an01034d. Epub 2021 Jul 28.
Herein, we proposed a novel biosensor based on a high-density "hot spot" Au@SiO array substrate and rolling circle amplification (RCA) strategy for the ultrasensitive detection of CpG methyltransferase (M.SssI) activity. In the presence of M.SssI, the RCA process can be triggered, causing the augmentation of the single-stranded DNA (ssDNA) at the tail of the double-stranded DNA (dsDNA), and the ssDNA can be hybridized with numerous DNA probes labeled with Raman reporters in the next steps. Afterwards, the resultant ssDNA can be modified to the Au@SiO array substrate with the SERS enhancement factor of 7.49 × 10. The substrate was synthesized by using a monolayer SiO array to pick up the Au nanoparticle (AuNP) array and finite-difference time-domain (FDTD) simulation showed its excellent SERS effect. Particularly, the developed biosensor displayed a significant sensitivity with a broad detection range covering from 0.005 to 50 U mL, and the limits of detection (LODs) in PBS buffer and human serum were 2.37 × 10 U mL and 2.51 × 10 U mL, respectively. Finally, in order to verify the feasibility of its clinical application, the serum samples of healthy subjects and breast cancer, prostate cancer, gastric cancer and cervical cancer patients were analyzed, and the reliability of the results was also confirmed by western blot (WB) experiments. Taking advantage of these merits, the proposed biosensor can be a very promising alternative tool for the detection of M.SssI activity, which is of vital importance in the early detection and prevention of tumors.
在这里,我们提出了一种基于高密度“热点”Au@SiO 阵列基底和滚环扩增(RCA)策略的新型生物传感器,用于超灵敏检测 CpG 甲基转移酶(M.SssI)活性。在 M.SssI 的存在下,RCA 过程可以被触发,导致双链 DNA(dsDNA)尾部的单链 DNA(ssDNA)扩增,并且 ssDNA 可以在下一步与标记有拉曼报告器的大量 DNA 探针杂交。之后,所得的 ssDNA 可以被修饰到具有 7.49×10 的 SERS 增强因子的 Au@SiO 阵列基底上。该基底是通过使用单层 SiO 阵列来收集 Au 纳米颗粒(AuNP)阵列合成的,有限差分时域(FDTD)模拟显示了其出色的 SERS 效应。特别是,所开发的生物传感器显示出显著的灵敏度,具有从 0.005 到 50 U mL 的宽检测范围,在 PBS 缓冲液和人血清中的检测限(LOD)分别为 2.37×10 U mL 和 2.51×10 U mL。最后,为了验证其临床应用的可行性,分析了健康受试者和乳腺癌、前列腺癌、胃癌和宫颈癌患者的血清样本,并且通过 Western blot(WB)实验也证实了结果的可靠性。利用这些优点,所提出的生物传感器可以成为检测 M.SssI 活性的非常有前途的替代工具,这对于肿瘤的早期检测和预防至关重要。